Compare · GILD vs PLUR
GILD vs PLUR
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Pluri Inc. (PLUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PLUR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $169.13B, about 6670.2x PLUR ($25.4M).
- Over the past year, GILD is up 22.6% and PLUR is down 43.4% - GILD leads by 66.0 points.
- GILD has been more active in the news (33 items in the past 4 weeks vs 2 for PLUR).
- GILD has more recent analyst coverage (25 ratings vs 0 for PLUR).
- Company
- Gilead Sciences Inc.
- Pluri Inc.
- Price
- $136.27+1.94%
- $2.52-28.06%
- Market cap
- $169.13B
- $25.4M
- 1M return
- +5.45%
- -24.63%
- 1Y return
- +22.64%
- -43.39%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 33
- 2
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
- FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC
- FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
- Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
- Gilead Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
Latest PLUR
- SEC Form 10-Q filed by Pluri Inc.
- Director Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Pluri Inc.
- SEC Form DEFA14A filed by Pluri Inc.
- SEC Form DEF 14A filed by Pluri Inc.
- Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
- Pluri Inc. filed SEC Form 8-K: Other Events
- Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
- SEC Form 10-Q filed by Pluri Inc.